Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
NCT03318445Phase 1Completed
- Sponsor
- Alessa Therapeutics
- Start
- Jan 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rucaparib in solid tumor (2 arms), sponsored by Alessa Therapeutics. Primary endpoint: Overall Response Rate up to 24 months. Started Jan 2018; status: completed.
02
Drugs
rucaparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03318445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03318445.